Popular weight-loss drugs included in FDA investigation: What to know

An FDA investigation of popular weight-loss drugs has generated a storm of media attention and prompted patient questions.
In its quarterly report, which was released on Tuesday, the agency revealed it is looking into potential safety signals of popular weight-loss drugs like Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk) Mounjaro (tirzepatide, Eli Lilly), Zepbound (tirzepatide, Eli Lilly) and Saxenda (liraglutide, Novo Nordisk). Semaglutide and liraglutide are both GLP-1 receptor agonists, whereas tirzepatide is a GIP/GLP-1 dual agonist, which has a different

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.